ClinicalTrials.gg
RecruitingNCT07383701Updated Sep 30, 2026

Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema

A Phase 2 interventional study of Lactobacillus plantarum 299v in Diabetic Macular Edema, sponsored by Massachusetts Eye and Ear Infirmary. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Massachusetts Eye and Ear Infirmary · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
135th of 244
36 · median 45
Started
2026
with 9 others
Phase 2
63 of 276
3 open now
Primary completion
2027-06
later than 18 of 31 live
Registered
267th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 135th largest by planned enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2026, is one of 63 in phase 2, reaches primary completion later than 18 of the 31 other live ones, and was the 267th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME).

The study seeks to address the following questions:

  1. Does central macular thickness on optical coherence tomography decrease after 4 months of supplementation?
  2. Is visual acuity improved at 1, 2, 3, and 4 months following initiation of supplementation?
  3. Is the number of anti-VEGF injections reduced following initiation of supplementation?

Outcomes will be compared to a control group, using historic retrospective data.

Participants will take Lactobacillus plantarum 299v orally twice daily for four months.

Read the detailed description

Study Design: Prospective open label longitudinal interventional study with oral probiotic supplement Lactobacillus plantarum.

Inclusion criteria: Age of at least 18 years, presence of DME at the current clinical visit

Exclusion criteria: Patients with contraindication to probiotic supplement (e.g. prior allergy or GI intolerance and any type of immunocompromised diseases).

Eligible individuals (patients at least 18 years old with diabetic macular

Participants: Patients with DME that belong in the following two groups:

  • Group A: 12 Patients with mild DME and good visual acuity (\<= 20/30) similar to DRCR network protocol V that do not need anti-VEGF injections as per standard clinical care.
  • Group B: 12 Patients with DME that need anti-VEGF injections as per standard clinical care.

Intervention: Oral probiotic supplement L. plantarum 299v twice daily for 4 months for both groups.

Study outcomes:

  • OCT with central macular thickness (CMT) at 1, 2, 3, 4-months follow-up.
  • Visual Acuity at 1, 2, 3, 4-months follow-up.
  • Number of anti VEGF injections.

In group A, the percentage of patients with a stability or improvement in DME as determined by a stability (+/- 9% of OCT CMT) or a reduction of DME (>= 30 microns or >= 10% decrease of CMT) from baseline will be measured. Secondary endpoints will be visual acuity and need for injection initiation during the 4 months.

In group B, the same outcomes as in group A will be measured. Furthermore, the number of injections group A over the course of 4 months will be evaluated.

Data from both groups will be compared to historical data available at the study site.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • diabetic macular edema
  • Lactiplantibacillus plantarum 299v
  • probiotic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of at least 18 years, presence of DME at the current clinical visit

Exclusion criteria

Exclusion Criteria:

  • Patients with to probiotic supplement (e.g. prior allergy or GI intolerance and any type of diseases).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Main Arm - twice daily for 4 months

    This is the only arm in this study. All participants will receive 4 months of Lactobacillus plantarum supplementation.

    Drug: Lactobacillus plantarum 299v

Interventions

06

What researchers measure

Primary outcomes

  1. Central Macular Thickness

    Central macular thickness (CMT) on optical coherence tomography

    Time frame: 1,2,3,4-months following supplement initiation

Secondary outcomes

  1. Best corrected visual acuity

    Best corrected visual acuity

    Time frame: 1, 2, 3, 4-months following supplement initiation

  2. Anti-VEGF Frequency

    Number of anti VEGF injections

    Time frame: At 1,2,3,4-months following supplement initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Senger DR, Li D, Jaminet SC, Cao S. Activation of the Nrf2 Cell Defense Pathway by Ancient Foods: Disease Prevention by Important Molecules and Microbes Lost from the Modern Western Diet. PLoS One. 2016 Feb 17;11(2):e0148042. doi: 10.1371/journal.pone.0148042. eCollection 2016. PubMed 26885667 ↗
  • Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89-116. doi: 10.1146/annurev.pharmtox.46.120604.141046. PubMed 16968214 ↗
  • Li JQ, Welchowski T, Schmid M, Letow J, Wolpers C, Pascual-Camps I, Holz FG, Finger RP. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020 Jan;35(1):11-23. doi: 10.1007/s10654-019-00560-z. Epub 2019 Sep 12. PubMed 31515657 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared. Although data would be de-identified, the small sample size and single-center design increase the risk of re-identification. Therefore, results will be reported in aggregate only. There are no current plans for external sharing of IPD.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Aug 2026 → Jun 2026 and primary completion Mar 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Jun 23, 2026was Aug 2026
Primary completionEst.
Jun 1, 2027was Mar 2027
CompletionEst.
Sep 1, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
Mass Eye and Ear is now Recruiting
Sep 30, 2026
Start date
Aug 1, 2026→Jun 23, 2026 (actual)
Sep 30, 2026
Primary completion
Mar 1, 2027→Jun 1, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    Mass Eye and Ear is now Recruiting
    Start date Aug 1, 2026→Jun 23, 2026 (now actual)
    Primary completion Mar 1, 2027→Jun 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07383701
Responsible party
Demetrios Vavvas (Solman and Libe Friedman Professor of Ophthalmology Director Retina Service Mass. Eye and Ear / Mass General Hospital Co-Director Ocular Regenerative Medical Institute Harvard Medical School, Massachusetts Eye and Ear Infirmary) — Principal investigator
First posted
Feb 3, 2026
Start date
Jun 23, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Demetrios G. Vavvas, MD PhD
Contact
Demetrios_Vavvas@meei.harvard.edu
6175736874

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactiplantibacillus plantarum 299V

Start the discussion